News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Insights
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Roche Says MabThera Gets Positive Phase III Data
October 26, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
ZURICH, Oct 26 (Reuters) - Lymph cancer treatment MabThera has been shown to work as a maintenance therapy in patients with relapsed indolent non-Hodgkin's lymphoma, according to initial details from a Phase III study released by Roche on Wednesday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase 3
Europe
Roche
MORE ON THIS TOPIC
Neuroscience
Ono cans 2 endocannabinoid drug studies after quintuple Phase 2 failure
October 29, 2026
·
1 min read
·
Annalee Armstrong
Insights
Stability, speed and strategy: Inside Australia’s early‑stage edge
October 29, 2026
·
1 min read
·
Jennifer C. Smith-Parker
Job Trends
Biopharma cuts at manufacturing plants expected to affect 4,000+
October 29, 2026
·
5 min read
·
Angela Gabriel
Cancer
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
October 28, 2026
·
2 min read
·
Nick Paul Taylor
